Biochemical Safety of SBRT to Multiple Intrahepatic Lesions for Hepatocellular Carcinoma

References

• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–491.e1. doi:10.1053/j.gastro.2018.08.065
   PubMed Web of Science ®Google Scholar
• Chamseddine I, Kim Y, De B, et al. Predictive model of liver toxicity to aid the personalized selection of proton vs photon therapy in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2023:S0360301623001049. doi:10.1016/j.ijrobp.2023.01.055
   Web of Science ®Google Scholar
• Russell AH, Clyde C, Wasserman TH, Turner SS, Rotman M. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the rtog dose escalating protocol. Int J Radiat Oncol Biol Phys. 1993;27(1):117–123. doi:10.1016/0360-3016(93)90428-X
   PubMed Web of Science ®Google Scholar
• Blomgren H, Lax I, Näslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator: clinical experience of the first thirty-one patients. Acta Oncologica. 1995;34(6):861–870. doi:10.3109/02841869509127197
   PubMed Web of Science ®Google Scholar
• Velec M, Haddad CR, Craig T, et al. Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2017;97(5):939–946. doi:10.1016/j.ijrobp.2017.01.221
   Web of Science ®Google Scholar
• Guha C, Kavanagh BD. Hepatic radiation toxicity: avoidance and amelioration. Sem rad Oncol. 2011;21(4):256–263. doi:10.1016/j.semradonc.2011.05.003
   PubMed Web of Science ®Google Scholar
• Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic Body Radiotherapy for Primary Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):e447–e453. doi:10.1016/j.ijrobp.2011.04.011
   PubMed Web of Science ®Google Scholar
• Wahl DR, Stenmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2016;34(5):452–459. doi:10.1200/JCO.2015.61.4925
   PubMed Web of Science ®Google Scholar
• Dewas S, Bibault JE, Mirabel X, et al. Prognostic factors affecting local control of hepatic tumors treated by stereotactic body radiation therapy. Radiat Oncol. 2012;7:166. doi:10.1186/1748-717X-7-166
   PubMed Web of Science ®Google Scholar
• Ohri N, Tomé WA, Romero AM, et al. Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys. 2018;S0360–3016(17):34525–X. doi:10.1016/j.ijrobp.2017.12.288
   Google Scholar
• Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. Radiother Oncol. 2019;131:135–144. doi:10.1016/j.radonc.2018.12.005
   PubMed Web of Science ®Google Scholar
• Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma. Ann Surg. 2006;243(2):229–235. doi:10.1097/01.sla.0000197706.21803.a1
   PubMed Web of Science ®Google Scholar
• N’Kontchou G, Mahamoudi A, Aout M, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009;50(5):1475–1483. doi:10.1002/hep.23181
   PubMed Web of Science ®Google Scholar
• Scorsetti M, Comito T, Cozzi L, et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol. 2015;141(7):1301–1309. doi:10.1007/s00432-015-1929-y
   PubMed Web of Science ®Google Scholar
• Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5):S35–S50. doi:10.1053/j.gastro.2004.09.014
   PubMed Web of Science ®Google Scholar
• Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Sem Rad Oncol. 2005;15(4):279–283. doi:10.1016/j.semradonc.2005.04.005
   PubMed Web of Science ®Google Scholar
• Miften M, Vinogradskiy Y, Moiseenko V, et al. Radiation dose-volume effects for liver SBRT. Int J Radiat Oncol Biol Phys. 2018;S0360–3016(17):34527. doi:10.1016/j.ijrobp.2017.12.290
   Google Scholar
• Owen D, Lukovic J, Hosni A, et al. Challenges in reirradiation of intrahepatic tumors. Sem Rad Oncol. 2020;30(3):242–252. doi:10.1016/j.semradonc.2020.02.004
   PubMed Web of Science ®Google Scholar
• Eriguchi T, Tsukamoto N, Kuroiwa N, et al. Repeated stereotactic body radiation therapy for hepatocellular carcinoma. Pract Radiat Oncol. 2021;11(1):44–52. doi:10.1016/j.prro.2020.08.002
   Web of Science ®Google Scholar
• Kimura T, Takeda A, Tsurugai Y, et al. A multi-institutional retrospective study of repeated stereotactic body radiation therapy for intrahepatic recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2020;108(5):1265–1275. doi:10.1016/j.ijrobp.2020.07.034
   Web of Science ®Google Scholar
• Sun J, Ouyang C, Chang X, et al. Repeated CyberKnife stereotactic body radiation therapy in hepatocellular carcinoma. Radiat Oncol. 2020;15(1):10. doi:10.1186/s13014-020-1457-z
   Web of Science ®Google Scholar
• McDuff SGR, Remillard KA, Zheng H, et al. Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Pract Radiat Oncol. 2018;8(6):414–421. doi:10.1016/j.prro.2018.04.012
   PubMed Web of Science ®Google Scholar
• Gkika E, Strouthos I, Kirste S, et al. Repeated SBRT for in- and out-of-field recurrences in the liver. Strahlenther Onkol. 2019;195(3):246–253. doi:10.1007/s00066-018-1385-0
   PubMed Web of Science ®Google Scholar
• Lo CH, Huang WY, Lin KT, Lin MJ, Lin TP, Jen YM. Repeated stereotactic ablative radiotherapy using CyberKnife for patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(11):1919–1925. doi:10.1111/jgh.12659
   Web of Science ®Google Scholar
• Oshiro Y, Mizumoto M, Okumura T, et al. Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma. Radiother Oncol. 2017;123(2):240–245. doi:10.1016/j.radonc.2017.03.004
   Web of Science ®Google Scholar
• Hashimoto T, Tokuuye K, Fukumitsu N, et al. Repeated proton beam therapy for hepatocellular carcinoma. Internat J Radiat Oncol Biol Phys. 2006;65(1):196–202. doi:10.1016/j.ijrobp.2005.11.043
   Web of Science ®Google Scholar
• Hasan S, Abel S, Jan I, Uemura T, Thai N, Kirichenko AV. The albumin-bilirubin (ALBI) model in hepatocellular carcinoma (HCC) may better predict hepatic failure in patients with traditionally low-risk cirrhosis following definitive stereotactic body radiotherapy (SBRT). J Radiat Oncol. 2018;7(3):247–253. doi:10.1007/s13566-018-0354-7
   Google Scholar
• Su TS, Yang HM, Zhou Y, et al. Albumin - bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy. Radiat Oncol. 2019;14(1):50. doi:10.1186/s13014-019-1251-y
   Google Scholar
• Moon DH, Wang AZ, Tepper JE. A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy. Radiother Oncol. 2018;126(3):527–533. doi:10.1016/j.radonc.2018.01.004
   Web of Science ®Google Scholar
• Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys. 1989;16(6):1623–1630. doi:10.1016/0360-3016(89)90972-3
   PubMed Web of Science ®Google Scholar
• Kutcher GJ, Burman C, Brewster L, Goitein M, Mohan R. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Internat J Radia Oncol Biol Phys. 1991;21(1):137–146. doi:10.1016/0360-3016(91)90173-2
   PubMed Web of Science ®Google Scholar
• Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Internat J Radia Oncol Biol Phys. 2002;53(4):810–821. doi:10.1016/S0360-3016(02)02846-8
   PubMed Web of Science ®Google Scholar
• Urata K, Kawasaki S, Matsunami H, et al. Calculation of child and adult standard liver volume for liver transplantation. Hepatology. 1995;21(5):1317–1321. doi:10.1016/0270-9139(95)90053-5
   PubMed Web of Science ®Google Scholar
• Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-Associated Liver Injury. Internat J Radia Oncol Biol Phys. 2010;76(3):S94–S100. doi:10.1016/j.ijrobp.2009.06.092
   PubMed Web of Science ®Google Scholar
• Cheng JCH, Wu JK, Huang CM, et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Internat J Radia Oncol Biol Phys. 2002;54(1):156–162. doi:10.1016/S0360-3016(02)02915-2
   PubMed Web of Science ®Google Scholar
• Hall J, Moon AM, Young M, et al. Liver toxicity following reirradiation and multiple-target SBRT for primary hepatocellular carcinoma. JCO. 2024;42(3_suppl):514. doi:10.1200/JCO.2024.42.3_suppl.514
   Google Scholar
• Apisarnthanarax S, Barry A, Cao M, et al. External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2022;12(1):28–51. doi:10.1016/j.prro.2021.09.004
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. JCO. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151
   PubMed Web of Science ®Google Scholar
• Lasley FD, Mannina EM, Johnson CS, et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a Phase 1–2 trial of stereotactic body radiation therapy. Pract Radiat Oncol. 2015;5(5):e443–e449. doi:10.1016/j.prro.2015.02.007
   PubMedGoogle Scholar
• Culleton S, Jiang H, Haddad CR, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol. 2014;111(3):412–417. doi:10.1016/j.radonc.2014.05.002
   PubMed Web of Science ®Google Scholar
• Wolf DC. Evaluation of the Size, Shape, and Consistency of the Liver. Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd. Butterworths: 1990. Available from: http://www.ncbi.nlm.nih.gov/books/NBK421/. Accessed September 4, 2023.
   Google Scholar
• Pollom EL, Chin AL, Diehn M, Loo BW, Chang DT. Normal tissue constraints for abdominal and thoracic stereotactic body radiotherapy. Sem rad Oncol. 2017;27(3):197–208. doi:10.1016/j.semradonc.2017.02.001
   PubMed Web of Science ®Google Scholar
• Hanna GG, Murray L, Patel R, et al. UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. Clin Oncol. 2018;30(1):5–14. doi:10.1016/j.clon.2017.09.007
   Google Scholar
• Cárdenes HR, Price TR, Perkins SM, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010;12(3):218–225. doi:10.1007/s12094-010-0492-x
   PubMed Web of Science ®Google Scholar
• Diez P, Hanna GG, Aitken KL, et al. UK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy. Clin Oncol. 2022;34(5):288–300. doi:10.1016/j.clon.2022.02.010
   Web of Science ®Google Scholar
• Cheng JCH, Wu JK, Lee PCT, et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys. 2004;60(5):1502–1509. doi:10.1016/j.ijrobp.2004.05.048
   Web of Science ®Google Scholar
• Xu ZY, Liang SX, Zhu J, et al. Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys. 2006;65(1):189–195. doi:10.1016/j.ijrobp.2005.11.034
   Web of Science ®Google Scholar
• D’Amico G, Morabito A, D’Amico M, et al. Clinical states of cirrhosis and competing risks. J Hepatol. 2018;68(3):563–576. doi:10.1016/j.jhep.2017.10.020
   PubMed Web of Science ®Google Scholar